Real-world clinical outcomes of treatment with brodalumab in patients with moderate-to-severe psoriasis: a retrospective, 24-month experience from four academic dermatology centers in Greece

Abstract

Objective

To assess the real-world clinical treatment outcomes with brodalumab in patients with moderate-to-severe plaque psoriasis in Greece.

Materials and methods

This was a longitudinal, retrospective, real-world analysis of data from medical records of 106 patients with moderate-to-severe plaque psoriasis, treated with brodalumab for up to 24 months at four University Dermatology Centers in Greece. Efficacy assessments of psoriasis severity [Psoriasis Area and Severity Index (PASI) and Body Surface Area affected (BSA) scores] and its impact on patients’ quality of life (QoL) [Dermatology Life Quality Index (DLQI) score] were evaluated at different timepoints up to 24 months.

Results

Treatment with brodalumab reduced both mean PASI (14.0–1.5, p < .001) and BSA scores (21.6–2.5, p < .001) across all visits. This effect was accompanied by reduction in mean DLQI score (12.8–2.1, p < .001) across all visits compared with baseline. Moreover, therapeutic efficacy was affected by prior biologic treatment exposure, as biologic naïve patients had greater reductions in all scores from baseline following treatment with brodalumab (numerical for mean PASI, significant for mean BSA and DLQI scores).

Conclusion

Brodalumab is effective long term, improving disease severity and health-related QoL in patients with moderate-to-severe plaque psoriasis in a real-world setting.

Keywords:

• Real-world data
• psoriasis
• brodalumab
• clinical response

Disclosure statement

Dr Papadavid reports there are no competing interests to declare.

Dr Zafeiriou reports personal fees from AbbVie, personal fees from Bioderma, personal fees from Eli Lilly, personal fees from Genesis Pharma, personal fees from LEO Pharma, personal fees from Novartis, personal fees from Principia Biopharma, personal fees from UCB and personal fees from Janssen, outside the submitted work.

Dr Georgiou reports personal fees from Abbvie, personal fees from Genesis Pharma, personal fees from Bristol Myers Squibb, personal fees from LEO Pharma, personal fees from Eli Lilly, personal fees from Novartis, personal fees from MEDA, personal fees from UCB, personal fees from Vianex, outside the submitted work.

Dr Roussaki-Schulze reports there are no competing interests to declare.

Dr Spiliopoulos has received personal fees from Janssen-Cilag Greece Pharmaceutical, personal fees from Genesis Pharma, and personal fees from LEO Pharma.

Dr Vryzaki reports there are no competing interests to declare.

Dr Oikonomou reports investigators fees from Genesis Pharma, LEO Pharma, AbbVie, Novartis and Janssen.

Dr Drongoula reports there are no competing interests to declare.

Dr Boziou reports there are no competing interests to declare.

Dr Goudouras reports there are no competing interests to declare.

Dr Sfaelos reports there are no competing interests to declare.

Dr Apalla reports personal fees from Abbvie, personal fees from Genesis Pharma, personal fees from Janssen, personal fees from LEO Pharma, personal fees from Sanofi, personal fees from L’Oreal, outside the submitted work.

Dr Lazaridou reports personal fees from Abbvie, personal fees from Genesis Pharma, personal fees from Janssen, personal fees from LEO Pharma, personal fees from Novartis, personal fees from Pharmaserve-Lilly, personal fees from MSD, personal fees from Roche, personal fees from Faran, outside the submitted work.

Data availability statement

The data that support the findings of this study are available from the corresponding author, upon reasonable request.

Additional information

Funding

Statistical analysis and medical writing were supported by LEO Pharma